Last reviewed · How we verify
Kenalog Injectable Product
Kenalog (triamcinolone acetonide) is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.
Kenalog (triamcinolone acetonide) is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors. Used for Intra-articular injection for rheumatoid arthritis and osteoarthritis, Soft tissue injection for bursitis, tendinitis, and other inflammatory conditions, Intralesional injection for keloids and hypertrophic scars.
At a glance
| Generic name | Kenalog Injectable Product |
|---|---|
| Sponsor | Hospital for Special Surgery, New York |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Rheumatology, Orthopedics, Immunology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone acetonide is a synthetic glucocorticoid that reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing immune cell activation and cytokine release. When injected directly into joints or soft tissues, it provides localized anti-inflammatory effects with systemic absorption.
Approved indications
- Intra-articular injection for rheumatoid arthritis and osteoarthritis
- Soft tissue injection for bursitis, tendinitis, and other inflammatory conditions
- Intralesional injection for keloids and hypertrophic scars
Common side effects
- Local pain or discomfort at injection site
- Temporary increase in joint pain (post-injection flare)
- Infection at injection site
- Systemic corticosteroid effects (with repeated injections)
- Skin atrophy at injection site
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Corticosteroid Meniscectomy Randomized Trial (PHASE4)
- Efficacy of Triamcinolone-Lidocaine Mix in Trigger Points Injection of Masseter Muscle: Double-blinded, Randomized Controlled Trial (PHASE2, PHASE3)
- NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis (PHASE3)
- Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients (PHASE2, PHASE3)
- Triple Therapy Strategy for Managing Persistent Pain After Spinal Microdiscectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kenalog Injectable Product CI brief — competitive landscape report
- Kenalog Injectable Product updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI